Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01880983 · ClinicalTrials.gov registry record
Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC))
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 150
- Enrollment target
NCT01880983 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 150 participants.
The verdict
NCT01880983 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to identify the biochemical/genetic defects in erythropoietic protoporphyria (EPP). People with EPP have skin sensitivity to sunlight and occasionally develop liver disease. In this study, the investigators hope to learn the nature of the biochemical/genetic defects in EPP because this may help explain the severity of these clinical features.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2011-11 |
| Est. Completion | 2020-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01880983
The ClinicalTrials.gov registry entry for NCT01880983 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01880983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01880983 about?
NCT01880983 is a clinical study titled "Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC))". The purpose of this study is to identify the biochemical/genetic defects in erythropoietic protoporphyria (EPP). People with EPP have skin sensitivity to sunlight and occasionally develop liver disease. In this study, the investigators hope to learn the nature of the biochemical/genetic defects in E...
What is the current status of trial NCT01880983?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2011-11. Estimated completion is 2020-12-31.
Who is sponsoring clinical trial NCT01880983?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.